Tim Wright, Editor06.02.16
Brammer Biopharmaceuticals recently merged with Florida Biologix to create a cell and gene therapy biologics contract development and manufacturing organization (CDMO). The merged company, Brammer Bio, is set up to combine technical expertise in process development and clinical manufacturing with capabilities, operating approaches and quality standards required for commercial manufacturing.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support enabling large pharma and biotech clients to accelerate the delivery of novel medicines.
Brammer Bio occupies 45,000 sq.-ft. of process development and Phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 sq.-ft. facility in Lexington, MA, with plans to build-out large-scale, Phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.
The man
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support enabling large pharma and biotech clients to accelerate the delivery of novel medicines.
Brammer Bio occupies 45,000 sq.-ft. of process development and Phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 sq.-ft. facility in Lexington, MA, with plans to build-out large-scale, Phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.
The man
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
